News
The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb-girdle ...
This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...
The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed ...
Sarepta Therapeutics (NASDAQ:SRPT) shares dropped sharply premarket on Monday before paring losses as Barclays revised its ...
In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...
Analysts’ view on the stock has dramatically changed over the past few months. Currently, only 21% of the 29 analysts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback